Mylan Laboratories (MYL) Receives Tentative FDA Approval for Generic Depakote ER
More News related to ABT
- Goldman Sachs Removed Abbott Labs (ABT) From Buy List, Eli Lilly (LLY) From Sell List
- Abbot Labs (ABT) To Transfer TriCor Rights to Teva Pharma (TEVA) as Soon as 2011
- Health Discovery Corporation Appoints Tom Gallagher, Former Wall Street Attorney & a Vice President at Goldman, Sachs & Co., to Head the Company's Global Intellectual Property Strategies
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- The Deal Names Abbott Top Dealmaker for Second Consecutive Year
More News related to MYL
- Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
- Mylan's Spanish Business Named Best Generic Pharmaceuticals Company in Spain by Elsevier
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
- Mylan Labs (MYL) Tops Q3 EPS by 5c, Guides Higher
More News related to FDA
- Dyax (DYAX) Receives FDA Approval of KALBITOR(R) for Treatment of Acute Attacks of Hereditary Angioedema
- Santarus (SNTS) Earns $20 Million Milestone on FDA Approval for NDA of ZEGERID
- Santarus (SNTS) Jumps Ahead of Expected News
- Hemispherx Biopharma (HEB) Receives Letter for Ampligen From US FDA; FDA Cannot Approve Application in Present Form
- Hemispherx (HEB) Falls 30% as FDA Recommends Another Ampligen Study, Says Can't Approve Application in Present Form
Mylan Laboratories Inc. (NYSE: MYL) announced that Mylan Pharmaceuticals Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Divalproex Sodium Extended-release (ER) Tablets, 250mg and 500mg strengths.
Divalproex Sodium ER Tablets are the generic version of Abbot Laboratories' (NYSE: ABT) Depakote ER® Tablets, which had U.S. sales of approximately $698 million for the same strengths for the 12-month period ending Dec. 31, 2006, according to IMS Health.
Related Categories
FDAStocks Mentioned
-0.01
+0.36Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
